Breast cancer biomarkers, and a new clinical category for HER2 expression

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer - Laboratory Investigation

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer - Laboratory Investigation

MLO LABline Daily - Feb 24th, 2024

Frontiers HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond - ScienceDirect

HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in‐situ hybridisation - Koopman - 2018 - Histopathology - Wiley Online Library

Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center - Modern Pathology

October 2022 Medical Laboratory Observer

MLO LABline Daily - Mar 5th, 2024

Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer

Breast Cancer and Hormone Receptor Positive Status - Moose and Doc

Targeting HER2 expression in cancer: New drugs and new indications